Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRG Bullfrog AI	$1.51 -3.8%	$1.74	$1.23 ▼ $4.84	$14.22M	0.61	399,777 shs	127,711 shs
CMMB Chemomab Therapeutics	$1.17 -2.0%	$1.28	$0.87 ▼ $2.55	$22.06M	0.47	219,735 shs	69,875 shs
EVOK Evoke Pharma	$2.63 -0.4%	$3.04	$1.94 ▼ $12.32	$3.92M	0.04	125,133 shs	9,949 shs
MIRA MIRA Pharmaceuticals	$1.25 +2.9%	$1.22	$0.51 ▼ $5.01	$21.07M	1.96	2.21 million shs	76,588 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRG Bullfrog AI	-3.82%	-8.48%	-14.20%	-11.18%	-12.72%
CMMB Chemomab Therapeutics	-1.98%	-2.50%	-14.60%	+3.54%	+17.00%
EVOK Evoke Pharma	-0.38%	-2.05%	-25.28%	-5.73%	-59.41%
MIRA MIRA Pharmaceuticals	+2.89%	+2.05%	-7.09%	+17.45%	+76.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRG Bullfrog AI	1.0155 of 5 stars	0.0	4.0	2.2	2.5	0.0
CMMB Chemomab Therapeutics	2.7883 of 5 stars	3.5	3.0	2.7	1.7	0.6
EVOK Evoke Pharma	1.173 of 5 stars	0.0	5.0	2.9	0.0	0.6
MIRA MIRA Pharmaceuticals	2.9049 of 5 stars	3.7	5.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	626.50% Upside
EVOK Evoke Pharma	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	1,024.50% Upside

Current Analyst Ratings Breakdown

Latest EVOK, MIRA, CMMB, and BFRG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/16/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$11.00 ➝ $10.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRG Bullfrog AI	$60K	237.07	N/A	N/A	$0.57 per share	2.65
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
EVOK Evoke Pharma	$10.25M	0.38	N/A	N/A	$4.74 per share	0.55
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRG Bullfrog AI	-$6.99M	-$0.81	N/A	∞	N/A	N/A	-163.23%	-139.94%	N/A
CMMB Chemomab Therapeutics	-$13.94M	-$0.76	N/A	N/A	N/A	N/A	-106.70%	-82.18%	8/20/2025 (Estimated)
EVOK Evoke Pharma	-$5.35M	-$2.87	N/A	∞	N/A	-43.80%	-101.91%	-33.75%	8/11/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.51	N/A	N/A	N/A	N/A	-341.08%	-272.93%	8/12/2025 (Estimated)

Latest EVOK, MIRA, CMMB, and BFRG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A
5/13/2025	Q1 2025	BFRG Bullfrog AI	N/A	-$0.21	N/A	-$0.21	N/A	N/A
5/12/2025	Q1 2025	EVOK Evoke Pharma	-$0.33	-$0.51	-$0.18	-$0.51	$3.32 million	$3.08 million
3/28/2025	Q4 2024	MIRA MIRA Pharmaceuticals	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRG Bullfrog AI	N/A	4.87	4.87
CMMB Chemomab Therapeutics	N/A	5.33	5.33
EVOK Evoke Pharma	N/A	1.55	1.50
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRG Bullfrog AI	0.96%
CMMB Chemomab Therapeutics	46.05%
EVOK Evoke Pharma	N/A
MIRA MIRA Pharmaceuticals	35.16%

Insider Ownership

Company	Insider Ownership
BFRG Bullfrog AI	33.90%
CMMB Chemomab Therapeutics	11.91%
EVOK Evoke Pharma	2.29%
MIRA MIRA Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRG Bullfrog AI	4	9.42 million	6.22 million	Not Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
EVOK Evoke Pharma	4	1.49 million	1.46 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	16.92 million	15.80 million	Not Optionable

EVOK, MIRA, CMMB, and BFRG Headlines

Recent News About These Companies

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - El Paso Times

June 26 at 7:37 PM | elpasotimes.comE

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Des Moines Register

June 26 at 7:37 PM | desmoinesregister.comD

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - The Columbus Dispatch

June 26 at 7:37 PM | dispatch.com

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Milwaukee Journal Sentinel

June 26 at 7:37 PM | jsonline.comJ

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Courier-Journal

June 26 at 7:37 PM | courier-journal.comC

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - azcentral.com

June 26 at 7:37 PM | azcentral.comA

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - Asbury Park Press

June 26 at 7:37 PM | app.comA

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Journal News or lohud.com

June 26 at 7:37 PM | lohud.comL

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without ...

June 26 at 12:11 PM | finanznachrichten.de

MIRA Announces Positive Test Results from Acquisition

June 26 at 2:42 AM | finance.yahoo.com

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 – A Drug Candidate Pending Acquisition – To Disrupt Weight Loss and Smoking Cessation Markets ...

June 25 at 10:18 AM | tennessean.comT

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

June 25 at 8:00 AM | accessnewswire.comA

MIRA Gets Validation from Journal

June 18, 2025 | finance.yahoo.com

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

June 18, 2025 | accessnewswire.comA

MIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology Journal

June 17, 2025 | tipranks.com

Visionstate Launches MIRA to Digitize Facility Inspections and Expand SaaS Platform

June 5, 2025 | thenewswire.comT

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 28, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Appoints New Chief Financial Officer

May 21, 2025 | tipranks.com

MIRA Releases Financials as Research Continues

May 15, 2025 | finance.yahoo.com

MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M

May 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, MIRA, CMMB, and BFRG Company Descriptions

Bullfrog AI NASDAQ:BFRG

$1.51 -0.06 (-3.82%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.05 (+3.64%)

As of 06/27/2025 05:23 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Chemomab Therapeutics NASDAQ:CMMB

$1.17 -0.02 (-1.98%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$1.17 0.00 (0.00%)

As of 06/27/2025 07:04 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Evoke Pharma NASDAQ:EVOK

$2.60 -0.04 (-1.52%)

As of 06/27/2025 04:00 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.25 +0.04 (+2.89%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.72%)

As of 06/27/2025 08:00 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time